Close menu




March 3rd, 2022 | 10:47 CET

Palantir, Perimeter Medical Imaging AI, Steinhoff - The scenario of the future

  • Technology
Photo credits: pixabay.com

Robots and algorithms are increasingly taking over work currently still done by humans. The Internet of Things, digitalization and artificial intelligence are topics we are increasingly coming into contact with. The possibilities in a digitally networked world are almost unlimited, which applies across all sectors. In medicine, artificial intelligence can be an essential decision-making aid for doctors. But it is also assuming an increasingly important position in the military sector, as was demonstrated during the recent Munich Security Conference.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: PALANTIR TECHNOLOGIES INC | US69608A1088 , PERIMETER MED.IMAG.AI | CA71385D1078 , STEINHOFF INT.HLDG.EO-_50 | NL0011375019

Table of contents:


    Palantir - Puzzle piece in modern warfare

    The war in Ukraine rages on, sanctions against Russia are getting tougher by the day, and countries are drastically increasing arms spending. Issues that at least Western European society has been spared in recent decades are now taking center stage in our daily affairs. As morbid as it sounds, as seen in the example of the Corona pandemic, there are not only losers but also companies that can profit from crises. In the case of modern warfare, this could be the US data analysis company Palantir Technologies. At the recent Munich Security Conference, Palantir CEO Alex Karp advocated using AI technology in the European military. It would be the factor to defend the fundamental values of states in the future.

    Palantir, which generates more than half of its revenue from US government, intelligence and law enforcement contracts, advises Europe to dominate AI in the military. In the US, people are convinced of the reliability of the data analytics platform. For example, the Denver-based Company received a USD 34 million procurement contract from the US Army to further develop the Army Intelligence Data Platform (AIDP), an AI-powered battle management analytics system. The US military uses the platform to predict where militias or opposing armies will place ground mines, for example, to attack US forces' convoys of vehicles.

    Palantir's stock has suffered heavy losses in recent months, falling from a high of USD 45 to a current USD 12.18. From a chart perspective, the resistance area at USD 9.75 was defended so that a trend reversal could begin here. However, the title is speculative, but the potential to become one of the most important technology companies in the next few years is still there.

    Perimeter Medical Imaging AI - The medical technology of the future

    Whether Palantir's technology is ethically correct remains to be seen. In contrast, the development of the medical technology company Perimeter Medical Imaging AI is groundbreaking and indeed serves the good of humanity. The Company has an office in Ontario, Canada, in addition to its headquarters in Dallas in the US. It aims to transform cancer surgery with ultra-high resolution, real-time advanced imaging tools to address unmet medical needs. Its proprietary technology enables surgeons, radiologists and pathologists to visualize microscopic tissue structures at surgical margins during and after clinical procedures.

    The Company, listed on the Toronto Stock Exchange, on Nasdaq and in Frankfurt with the abbreviation PINK and has a current market capitalization of EUR 120.06 million, has already made substantial progress in the past year. One of its key achievements was 510(k) clearance from the Food and Drug Administration, enabling the commercial launch of its flagship Perimeter S-Series OCT platform. In addition, a multi-center, randomized, two-arm clinical trial of the Perimeter B-Series OCT platform in combination with ImgAssist AI was initiated and continues to enroll patients and is expected to be completed later this year.

    Financially, further growth was secured with the raising of USD 48.7 million. It is also expected to accelerate sales and marketing efforts to place the flagship Perimeter S-Series OCT product in leading hospitals where key opinion leaders can advocate the technology. In parallel, Perimeter's clinical team will focus on continued patient recruitment and healthcare provider engagement in the ongoing pivotal study evaluating next-generation Perimeter B-Series OCT with ImgAssist AI in breast lumpectomy. The goal is to collect data from approximately 300 patients at 8 sites and complete the study in 2022.

    Steinhoff - Underwhelmed

    It is not so much about the move to artificial intelligence at global retailer Steinhoff, headquartered in Amsterdam. Instead, management continues to struggle to come to terms with the past. The Company is now in the final phase of its three-stage turnaround strategy, which focuses on reducing debt and making its balance sheet sustainable.

    Recently, the figures for the fourth quarter of 2021 were presented. The group reported a 10% increase to EUR 2.827 billion in terms of revenue. For Steinhoff's US investment Mattress Firm, an increase in quarterly revenue from EUR 785 million to EUR 987 million was reported. "The group's main focus is now on implementing step three of the three-step strategy plan - addressing the high level of debt," Steinhoff said in a statement.

    After the strong performance and the bounce off the EUR 0.30 mark, the share price had to give way again significantly and temporarily fell below the EUR 0.20 mark. The next test is the support area at EUR 0.18. Given the extreme debts of an assumed magnitude of almost EUR 10 billion, an investment continues to resemble a game of roulette.


    Artificial intelligence continues to advance and can be found in nearly every industry. Given the current geopolitical situation, Palantir could benefit from its AI-powered battle management analysis system and subsequent government contracts from Western countries. Perimeter is pioneering the fight against breast cancer and could surprise positively when further study results are published. Steinhoff remains highly speculative.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on May 17th, 2022 | 14:14 CEST

    Nel share with a tailwind, but what are TeamViewer and Aspermont doing?

    • Technology
    • Digitization

    Last week was disastrous for many technology stocks. In this environment, the Nel share showed strength and yesterday, it also performed positively in a relatively weak environment. That is because there is currently a tailwind for the hydrogen specialist from a wide variety of places: analysts, the European Union and even a king. At least analysts are also convinced of Aspermont. After the positive figures, investors are hoping for new impetus from the technology company's presentation at a virtual investor conference. At TeamViewer, analyst comments are mixed, but the price targets are attractive.

    Read

    Commented by Nico Popp on May 16th, 2022 | 12:48 CEST

    Future Tech check: BASF, Meta Materials, BYD, Rock Tech Lithium

    • metamaterials
    • Technology

    What will drive share prices in the future is more uncertain than ever. The sword of Damocles of the recession is currently hovering over many future topics. But should long-term investors be driven by fear of recession? On the contrary! Now is the best time to consider investments for the future. The good thing is that thorough due diligence can pay off twice over. First, it increases the chances of hitting the bull's eye, and second, the prices may even suit investors. We take a closer look at three shares!

    Read

    Commented by André Will-Laudien on May 10th, 2022 | 11:54 CEST

    GreenTech stocks are on the rise! Buy now: BASF, Meta Materials, Nordex, Siemens Energy

    • GreenTech
    • Technology
    • Investments

    The distortions on the capital markets can hardly be topped at the moment. The nickel price has risen by 300%, only to drop by 70% again. And all this in only 48 hours. There are countless examples in the current stock market environment that are historically unparalleled. In just 2 months, the Bund Future fell from 178 to 151, a loss of 16% in the 10-year Bund. In parallel, the capital market interest rate rose from minus 0.45% to a whopping plus 1.15%. So interest rates are back, inflation is spreading, and supply deficits continue to fuel the underlying stagflation scenario! One major trend should bounce back after the end of the many corrections: GreenTech! Here is a selection of interesting stocks.

    Read